Summary: Featuring articles on evolocumab and cardiovascular outcomes, tofacitinib for ulcerative colitis, bystander efforts in out-of-hospital cardiac arrest, and teprotumumab for thyroid-associated ophthalmopathy; review articles on partnerships among researchers, patient groups, and industry and on acute kidney injury in patients with cancer; a Clinical Problem-Solving article on going back to the history; and Perspective articles on why Trump’s NIH funding cuts would be a disaster, on resident duty hours, on how the FDA saved taxpayers billions, and on health insurance and emergency department use.
